Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SACUI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
BB-1705
|
|||||
| Synonyms |
BB-1705
Click to Show/Hide
|
|||||
| Organization |
Bliss Biopharmaceutical (BlissBio) (Originator);Morphotek
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-EGFR antibody
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
Eribulin
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mal-PEG2-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
ecteribulin
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients are adults (≥18 years) with histologically confirmed advanced/metastatic solid tumors (RECIST 1.1 measurable lesions), ECOG 0-1, and adequate organ function. Key exclusions include recent anticancer therapy, uncontrolled CNS metastases, ≥Grade 2 peripheral neuropathy, active pneumonitis/ILD, or significant comorbidities (e.g., QTc prolongation). Contraception is required during treatment and for 6 months post-dose.
Click to Show/Hide
|
||||
| Administration Dosage |
BB-1705 will be administered as an intravenous infusion by Q3W for 8cycles
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05217693 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase I First-in-human, Open Label, Multicenter, Dose Escalation and Cohort Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of BB-1705 in Patients With Locally Advanced/Metastatic Solid Tumors | ||||
| Primary Endpoint |
The study evaluates safety by monitoring adverse events (AEs) and serious adverse events (SAEs) for up to 2 years, with dose-limiting toxicities (DLTs) assessed during Cycle 1 (21 days) to determine the maximum tolerated dose (MTD) based on NCI-CTCAE criteria.
|
||||
| Other Endpoint |
Pharmacokinetic analysis includes AUC0-inf and Cmax measurements during Cycles 1-8 (21-day cycles), while immunogenicity is assessed via anti-drug antibodies (ADAs). Efficacy endpoints include objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR) evaluated every 6-9 weeks for up to 2 years.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05217693 | Clinical Status | Phase 1/2 | ||
| Clinical Description | A phase 1/2 first-in-human, open label, multicenter, dose escalation and cohort expansion study to investigate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of BB-1705 in patients with locally advanced/metastatic solid tumors. | ||||
References